title: Polycystic ovary syndrome and environmental toxins.
abstract: Polycystic ovary syndrome (PCOS) is the most common, heterogeneous, and multifactorial endocrine disorder in premenopausal women. The pathophysiology of this endocrinopathy is still unclear; however, the heterogeneity of its features within ethnic races, geographic location, and families suggests that environment and lifestyle are of prime importance. This work is mainly focused on the possible role of the most common and studied environmental toxins for this syndrome in the pathogenesis of PCOS. Plasticizers, such as bisphenol A (BPA) or phthalates, which belong to the categories of endocrine disrupting chemicals (EDCs) and advanced glycation end products (AGEs), affect humans' health in everyday, industrialized life; therefore special attention should be paid to such exposure. Timing of exposure to EDCs is crucial for the intensity of adverse health effects. It is now evident that fetuses, infants, and/or young children are the most susceptible groups, especially in the early development periods. Prenatal exposure to EDCs that mimic endogenous hormones may contribute to the altered fetal programming and in consequence lead to PCOS and other adverse health effects, potentially transgenerationally. Acute or prolonged exposure to EDCs and AGEs through different life cycle stages may result in destabilization of the hormonal homeostasis and lead to disruption of reproductive functions. They may also interfere with metabolic alterations such as obesity, insulin resistance, and compensatory hyperinsulinemia that can exacerbate the PCOS phenotype and contribute to PCOS consequences such as type 2 diabetes and cardiovascular disease. Since wide exposure to environmental toxins and their role in the pathophysiology of PCOS are supported by extensive data derived from diverse scientific models, protective strategies and strong recommendations should be considered to reduce human exposure to protect present and future generations from their adverse health effects.
authors: Department of Clinical and Experimental Endocrinology, Medical University of Gdansk, Gdansk, Poland.
authors: Aleksandra Zofia
authors: AZ
authors: Rutkowska
authors: Department of Endocrinology and Diabetes Center of Excellence, Medical School University of Athens, EUROCLINIC, Athens, Greece. Electronic address: e.diamanti.kandarakis@gmail.com.
authors: Evanthia
authors: E
authors: Diamanti-Kandarakis
mesh_terms: D000818:Animals; D052244:Endocrine Disruptors / Q000009:adverse effects*; D004781:Environmental Exposure / Q000009:adverse effects*; D004785:Environmental Pollutants / Q000009:adverse effects*; D005260:Female; D017127:Glycation End Products, Advanced / Q000378:metabolism; D012739:Gonadal Steroid Hormones / Q000096:biosynthesis; D006801:Humans; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D011085:Polycystic Ovary Syndrome / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D052244:Endocrine Disruptors; D004785:Environmental Pollutants; D017127:Glycation End Products, Advanced; D012739:Gonadal Steroid Hormones
keywords: Polycystic ovary syndrome; advanced glycation end products; bisphenol A; endocrine disrupting chemicals